Changes in angiotensin II receptor bindings in the hen neurohypophysis before and after oviposition.
The present study was performed to elucidate whether the angiotensin II (ANG II) receptor exists in the plasma membrane fraction of the neurohypophysis in hens, to estimate the time of action of ANG II on the neurohypophysis before and after oviposition, and to examine relationships between the action of ANG II on the neurohypophysis and those of estrogen and prostaglandin F(2α) (PGF(2α)) in relation to arginine vasotocin (AVT) release. The specific binding had a binding specificity to chicken ANG II (cANG II), reversibility, and saturation in the [(125)I]cANG II binding assay. Scatchard analysis revealed that the binding sites are of a single class. The equilibrium dissociation constant (K(d)) obtained by kinetic analysis and Scatchard analysis suggested a high affinity, and the maximum binding capacity (B(max)) obtained by Scatchard analysis suggested a limited capacity. These results suggest that an ANG II receptor exists in the neurohypophysis of hens. The K(d) and the B(max) value was significantly smaller in laying hens than in nonlaying hens, which suggests that bindings of the cANG II receptor change, depending on the difference in laying condition. Values of the K(d) and the B(max) decreased approximately 15 min before oviposition in laying hens, and decreased 1 h after an intramuscular injection of estradiol-17β and 5 min after an intravenous injection of cANG II in nonlaying hens. The amount of specific binding of PGF(2α) receptor in the neurohypophysis also decreased and AVT concentration in blood increased after the cANG II injection. It seems likely that the action of cANG II in the neurohypophysis increases due to the effect of estrogen approximately 15 min before oviposition, and the cANG II action stimulates AVT release through the increase in the PGF(2α) action in this tissue.
Department of Avian Endocrinology, Gifu University, Yanagido, Gifu, Japan.
T
T
Takahashi
Y
Y
Nozaki
K
K
Nakagawa-Mizuyachi
H
H
Nakayama
M
M
Kawashima
D000804:Angiotensin II / Q000494:pharmacology; D000809:Angiotensins / Q000378:metabolism; D000818:Animals; D002645:Chickens / Q000502:physiology*; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D010058:Oviposition / Q000502:physiology*; D010904:Pituitary Gland, Posterior / Q000187:drug effects / Q000502:physiology*; D011485:Protein Binding; D011945:Receptors, Angiotensin / Q000235:genetics / Q000378:metabolism*; D011982:Receptors, Prostaglandin / Q000378:metabolism; D014668:Vasotocin / Q000378:metabolism
D000809:Angiotensins; D011945:Receptors, Angiotensin; D011982:Receptors, Prostaglandin; C034671:prostaglandin F2alpha receptor; D000804:Angiotensin II; D004958:Estradiol; D014668:Vasotocin